Corticosteroid reduction by addition of cetirizine and montelukast in biopsy-proven minimal-change nephrotic syndrome concomitant with allergic disorders.
Acetates
/ administration & dosage
Adrenal Cortex Hormones
/ administration & dosage
Adult
Aged
Cetirizine
/ administration & dosage
Cyclopropanes
Female
Histamine H1 Antagonists, Non-Sedating
/ administration & dosage
Humans
Hypersensitivity
/ complications
Immunosuppressive Agents
/ administration & dosage
Leukotriene Antagonists
/ administration & dosage
Male
Middle Aged
Nephrosis, Lipoid
/ complications
Prednisolone
/ administration & dosage
Propensity Score
Quinolines
/ administration & dosage
Retrospective Studies
Sulfides
Treatment Outcome
Young Adult
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
30 01 2020
30 01 2020
Historique:
received:
10
10
2019
accepted:
16
01
2020
entrez:
1
2
2020
pubmed:
1
2
2020
medline:
18
11
2020
Statut:
epublish
Résumé
Recent reports suggest helper T-cell abnormalities in minimal-change nephrotic syndrome (MCNS), which often complicate allergic disorders that show a similar helper T-cell profile with Th2/Th17 predominance. However, the effect of anti-allergy therapy on MCNS remains unknown. This retrospective study included 51 patients with biopsy-proven MCNS recruited between November 2012 and October 2015, with follow-up through November 2017. We analyzed relapse and temporal daily corticosteroid dose with and without co-administration of histamine H1 receptor antagonist, cetirizine, and cysteinyl-leukotriene receptor antagonist, montelukast, as well as between baseline and after follow-up. Thirteen patients were treated with cetirizine and montelukast in addition to conventional therapy, whereas 38 patients were treated by conventional therapy only, consisting of corticosteroids and immunosuppressants. To adjust for baseline clinical characteristics, a 1:1 propensity score-matched model was applied. The clinical characteristics of the two groups after matching were similar at baseline. The treatment group showed a significant reduction in the lowest daily dose of oral prednisolone throughout the entire treatment course after the study compared to that of baseline (p < 0.025), which was not observed in the control group (p = 0.37), and showed significantly higher percentage of patients establishing corticosteroid-free state for the first time throughout the entire treatment course by addition of cetirizine and montelukast compared to the control group (p < 0.025). The study shows, for the first time, the steroid sparing effect of cetirizine and montelukast in addition to conventional treatment in MCNS patients with concomitant allergies.
Identifiants
pubmed: 32001777
doi: 10.1038/s41598-020-58463-z
pii: 10.1038/s41598-020-58463-z
pmc: PMC6992583
doi:
Substances chimiques
Acetates
0
Adrenal Cortex Hormones
0
Cyclopropanes
0
Histamine H1 Antagonists, Non-Sedating
0
Immunosuppressive Agents
0
Leukotriene Antagonists
0
Quinolines
0
Sulfides
0
Prednisolone
9PHQ9Y1OLM
montelukast
MHM278SD3E
Cetirizine
YO7261ME24
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1490Références
Komatsuda, A. et al. GATA-3 is upregulated in peripheral blood mononuclear cells from patients with minimal change nephrotic syndrome. Clin. Nephrol. 71, 608–616 (2009).
doi: 10.5414/CNP71608
Stangou, M. et al. Impact of Tauh1 and Tauh2 cytokines in the progression of idiopathic nephrotic syndrome due to focal segmental glomerulosclerosis and minimal change disease. J. nephropathology 6, 187–195, https://doi.org/10.15171/jnp.2017.32 (2017).
doi: 10.15171/jnp.2017.32
pubmed: 28975100
Cho, B. S., Yoon, S. R., Jang, J. Y., Pyun, K. H. & Lee, C. E. Up-regulation of interleukin-4 and CD23/FcepsilonRII in minimal change nephrotic syndrome. Pediatr. Nephrol. 13, 199–204 (1999).
doi: 10.1007/s004670050592
Yap, H. K. et al. Th1 and Th2 cytokine mRNA profiles in childhood nephrotic syndrome: evidence for increased IL-13 mRNA expression in relapse. J. Am. Soc. Nephrol. 10, 529–537 (1999).
pubmed: 10073603
van den Berg, J. G. & Weening, J. J. Role of the immune system in the pathogenesis of idiopathic nephrotic syndrome. Clin. Sci. 107, 125–136, https://doi.org/10.1042/cs20040095 (2004).
doi: 10.1042/cs20040095
pubmed: 15157184
Sahali, D. et al. A novel approach to investigation of the pathogenesis of active minimal-change nephrotic syndrome using subtracted cDNA library screening. J. Am. Soc. Nephrol. 13, 1238–1247 (2002).
pubmed: 11961011
Liu, L. L. et al. Th17/Treg imbalance in adult patients with minimal change nephrotic syndrome. Clin. Immunol. 139, 314–320, https://doi.org/10.1016/j.clim.2011.02.018 (2011).
doi: 10.1016/j.clim.2011.02.018
pubmed: 21450528
Salcido-Ochoa, F. et al. Analysis of T Cell Subsets in Adult Primary/Idiopathic Minimal Change Disease: A Pilot Study. Int. J. Nephrol. 2017, 3095425, https://doi.org/10.1155/2017/3095425 (2017).
doi: 10.1155/2017/3095425
pubmed: 28894608
pmcid: 5574215
Araya, C. et al. T regulatory cell function in idiopathic minimal lesion nephrotic syndrome. Pediatr. Nephrol. 24, 1691–1698, https://doi.org/10.1007/s00467-009-1214-x (2009).
doi: 10.1007/s00467-009-1214-x
pubmed: 19495805
pmcid: 2785122
Lee, H. J. et al. GATA-3 induces T helper cell type 2 (Th2) cytokine expression and chromatin remodeling in committed Th1 cells. J. Exp. Med. 192, 105–115 (2000).
doi: 10.1084/jem.192.1.105
Zhu, J. T helper 2 (Th2) cell differentiation, type 2 innate lymphoid cell (ILC2) development and regulation of interleukin-4 (IL-4) and IL-13 production. Cytokine 75, 14–24, https://doi.org/10.1016/j.cyto.2015.05.010 (2015).
doi: 10.1016/j.cyto.2015.05.010
pubmed: 26044597
pmcid: 4532589
Shi, Y. H. et al. Coexistence of Th1/Th2 and Th17/Treg imbalances in patients with allergic asthma. Chin. Med. J. 124, 1951–1956 (2011).
pubmed: 22088452
Endo, Y., Hirahara, K., Yagi, R., Tumes, D. J. & Nakayama, T. Pathogenic memory type Th2 cells in allergic inflammation. Trends Immunol. 35, 69–78, https://doi.org/10.1016/j.it.2013.11.003 (2014).
doi: 10.1016/j.it.2013.11.003
pubmed: 24332592
Roesner, L. M. et al. Der p1 and Der p2-Specific T Cells Display a Th2, Th17, and Th2/Th17 Phenotype in Atopic Dermatitis. J. Invest. Dermatol. 135, 2324–2327, https://doi.org/10.1038/jid.2015.162 (2015).
doi: 10.1038/jid.2015.162
pubmed: 25918982
Gu, Z. W., Wang, Y. X. & Cao, Z. W. Neutralization of interleukin-17 suppresses allergic rhinitis symptoms by downregulating Th2 and Th17 responses and upregulating the Treg response. Oncotarget 8, 22361–22369, https://doi.org/10.18632/oncotarget.15652 (2017).
doi: 10.18632/oncotarget.15652
pubmed: 28423590
pmcid: 5410229
Packard, K. A. & Khan, M. M. Effects of histamine on Th1/Th2 cytokine balance. Int. Immunopharmacol. 3, 909–920, https://doi.org/10.1016/s1567-5769(02)00235-7 (2003).
doi: 10.1016/s1567-5769(02)00235-7
pubmed: 12810348
Fujimoto, S. et al. Histamine differentially regulates the production of Th1 and Th2 chemokines by keratinocytes through histamine H1 receptor. Cytokine 54, 191–199, https://doi.org/10.1016/j.cyto.2010.12.012 (2011).
doi: 10.1016/j.cyto.2010.12.012
pubmed: 21324712
Mazzoni, A., Young, H. A., Spitzer, J. H., Visintin, A. & Segal, D. M. Histamine regulates cytokine production in maturing dendritic cells, resulting in altered T cell polarization. J. Clin. Invest. 108, 1865–1873, https://doi.org/10.1172/jci13930 (2001).
doi: 10.1172/jci13930
pubmed: 11748270
pmcid: 209473
Mommert, S., Gschwandtner, M., Koether, B., Gutzmer, R. & Werfel, T. Human memory Th17 cells express a functional histamine H4 receptor. Am. J. Pathol. 180, 177–185, https://doi.org/10.1016/j.ajpath.2011.09.028 (2012).
doi: 10.1016/j.ajpath.2011.09.028
pubmed: 22063299
Xue, L. et al. Prostaglandin D2 and leukotriene E4 synergize to stimulate diverse TH2 functions and TH2 cell/neutrophil crosstalk. J. Allergy Clin. Immunol. 135(1358–1366), e1351–1311, https://doi.org/10.1016/j.jaci.2014.09.006 (2015).
doi: 10.1016/j.jaci.2014.09.006
Lee, W., Su Kim, H. & Lee, G. R. Leukotrienes induce the migration of Th17 cells. Immunol. Cell Biol. 93, 472–479, https://doi.org/10.1038/icb.2014.104 (2015).
doi: 10.1038/icb.2014.104
pubmed: 25512344
Xiao, J., Wu, W. X., Ye, Y. Y., Lin, W. J. & Wang, L. A Network Meta-analysis of Randomized Controlled Trials Focusing on Different Allergic Rhinitis Medications. Am. J. Ther. 23, e1568–e1578, https://doi.org/10.1097/mjt.0000000000000242 (2016).
doi: 10.1097/mjt.0000000000000242
pubmed: 25867532
Wei, C. The efficacy and safety of H1-antihistamine versus Montelukast for allergic rhinitis: A systematic review and meta-analysis. Biomed. Pharmacother. 83, 989–997, https://doi.org/10.1016/j.biopha.2016.08.003 (2016).
doi: 10.1016/j.biopha.2016.08.003
pubmed: 27522261
Zhang, H. P., Jia, C. E., Lv, Y., Gibson, P. G. & Wang, G. Montelukast for prevention and treatment of asthma exacerbations in adults: Systematic review and meta-analysis. Allergy Asthma Proc. 35, 278–287, https://doi.org/10.2500/aap.2014.35.3745 (2014).
doi: 10.2500/aap.2014.35.3745
pubmed: 24992547
Sharma, M., Bennett, C., Carter, B. & Cohen, S. N. H1-antihistamines for chronic spontaneous urticaria: an abridged Cochrane Systematic Review. J. Am. Acad. Dermatol. 73, 710–716, e714, https://doi.org/10.1016/j.jaad.2015.06.048 (2015).
doi: 10.1016/j.jaad.2015.06.048
pubmed: 26253363
de Silva, N. L., Damayanthi, H., Rajapakse, A. C., Rodrigo, C. & Rajapakse, S. Leukotriene receptor antagonists for chronic urticaria: a systematic review. Allergy Asthma Clin. Immunol. 10, 24, https://doi.org/10.1186/1710-1492-10-24 (2014).
doi: 10.1186/1710-1492-10-24
pubmed: 24817895
pmcid: 4016797
Roekevisch, E., Spuls, P. I., Kuester, D., Limpens, J. & Schmitt, J. Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review. J. Allergy Clin. Immunol. 133, 429–438, https://doi.org/10.1016/j.jaci.2013.07.049 (2014).
doi: 10.1016/j.jaci.2013.07.049
pubmed: 24269258
Austin, P. C. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat. Med. 28, 3083–3107, https://doi.org/10.1002/sim.3697 (2009).
doi: 10.1002/sim.3697
pubmed: 19757444
pmcid: 3472075
Zedan, M. M. et al. Montelukast as an add-on treatment in steroid dependant nephrotic syndrome, randomised-controlled trial. J. nephrology 29, 585–592, https://doi.org/10.1007/s40620-016-0297-2 (2016).
doi: 10.1007/s40620-016-0297-2
Abdel-Hafez, M., Shimada, M., Lee, P. Y., Johnson, R. J. & Garin, E. H. Idiopathic nephrotic syndrome and atopy: is there a common link? Am. J. Kidney Dis. 54, 945–953, https://doi.org/10.1053/j.ajkd.2009.03.019 (2009).
doi: 10.1053/j.ajkd.2009.03.019
pubmed: 19556042
pmcid: 2895907
Schulte-Wissermann, H., Gortz, W. & Straub, E. IgE in patients with glomerulonephritis and minimal-change nephrotic syndrome. Eur. J. Pediatr. 131, 105–111, https://doi.org/10.1007/bf00447472 (1979).
doi: 10.1007/bf00447472
pubmed: 378666
Fuke, Y. et al. Implication of elevated serum IgE levels in minimal change nephrotic syndrome. Nephron 91, 769–770, https://doi.org/10.1159/000065049 (2002).
doi: 10.1159/000065049
pubmed: 12138291
Miyazaki, K. et al. GSTT1 gene abnormality in minimal change nephrotic syndrome with elevated serum immunoglobulin E. Clin. Nephrol. 77, 261–266, https://doi.org/10.5414/cn107187 (2012).
doi: 10.5414/cn107187
pubmed: 22445468
Bertelli, R., Bonanni, A., Caridi, G., Canepa, A. & Ghiggeri, G. M. Molecular and Cellular Mechanisms for Proteinuria in Minimal Change Disease. Front. Med. 5, 170, https://doi.org/10.3389/fmed.2018.00170 (2018).
doi: 10.3389/fmed.2018.00170
Pirotzky, E. et al. Basophil sensitisation in idiopathic nephrotic syndrome. Lancet 1, 358–361 (1982).
doi: 10.1016/S0140-6736(82)91391-5